CO5261585A1 - Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion - Google Patents

Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion

Info

Publication number
CO5261585A1
CO5261585A1 CO01014634A CO01014634A CO5261585A1 CO 5261585 A1 CO5261585 A1 CO 5261585A1 CO 01014634 A CO01014634 A CO 01014634A CO 01014634 A CO01014634 A CO 01014634A CO 5261585 A1 CO5261585 A1 CO 5261585A1
Authority
CO
Colombia
Prior art keywords
glutamic
oxo
amino
acid
crystal form
Prior art date
Application number
CO01014634A
Other languages
English (en)
Inventor
Erick Christopher Chelius
Susan Marie Reutzel-Edens
Van Den Berghe Snorek Sharon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22679017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5261585(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5261585A1 publication Critical patent/CO5261585A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una nueva forma de cristal hidrato de la sal disódica del ácido N-[4-[2-(2-amino-4,7-dihidro-4-oxo-3H-pirrolo[2,3-d]-pirimidin-5-il)etil]benzoil]-L-glutámico ("forma cristalina heptahidrato"), que tiene un modelo de difracción de rayos X característico que comprende los siguientes picos correspondientes a distancias interplanares d: 7,78 /-0,04 Å cuando se obtiene a 22 2°C y con un % de humedad relativa ambiental a partir de una fuente de radiación de cobre.<EMI FILE="01014634_1" ID="1" IMF=JPEG >
CO01014634A 2000-02-25 2001-02-23 Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion CO5261585A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18496400P 2000-02-25 2000-02-25

Publications (1)

Publication Number Publication Date
CO5261585A1 true CO5261585A1 (es) 2003-03-31

Family

ID=22679017

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01014634A CO5261585A1 (es) 2000-02-25 2001-02-23 Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion

Country Status (36)

Country Link
US (1) US7138521B2 (es)
EP (1) EP1259513B1 (es)
JP (1) JP4846158B2 (es)
KR (1) KR100744917B1 (es)
CN (1) CN1183135C (es)
AR (1) AR029471A1 (es)
AT (1) ATE249462T1 (es)
AU (1) AU777047B2 (es)
BR (1) BR0108604A (es)
CA (1) CA2400155C (es)
CO (1) CO5261585A1 (es)
CZ (1) CZ303772B6 (es)
DE (1) DE60100750T2 (es)
DK (1) DK1259513T3 (es)
DZ (1) DZ3283A1 (es)
EA (1) EA004684B1 (es)
EG (1) EG24073A (es)
ES (1) ES2206403T3 (es)
HK (1) HK1051856A1 (es)
HR (1) HRP20020701B1 (es)
HU (1) HU229704B1 (es)
IL (2) IL150480A0 (es)
MX (1) MXPA02008242A (es)
MY (1) MY124784A (es)
NO (1) NO323422B1 (es)
NZ (1) NZ519796A (es)
PE (1) PE20011082A1 (es)
PL (1) PL208061B1 (es)
PT (1) PT1259513E (es)
SI (1) SI1259513T1 (es)
SK (1) SK287375B6 (es)
SV (1) SV2002000321A (es)
TW (1) TWI237024B (es)
UA (1) UA72791C2 (es)
WO (1) WO2001062760A2 (es)
ZA (1) ZA200205265B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364993C (zh) * 2003-05-30 2008-01-30 江苏恒瑞医药股份有限公司 培美曲噻盐及其制备方法
CN100364994C (zh) * 2004-11-25 2008-01-30 重庆医药工业研究院有限责任公司 培美曲塞二钠的一种新晶型及其制备方法
JP2009514889A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためにｓａｈａ及びボルテゾミブを用いる方法
CA2622136A1 (en) * 2005-11-04 2007-05-18 Merck & Co., Inc. Methods of using saha and erlotinib for treating cancer
US7994180B2 (en) * 2006-08-14 2011-08-09 Sicor Inc. Processes for preparing intermediates of pemetrexed
JP2008543975A (ja) * 2006-08-14 2008-12-04 シコール インコーポレイティド 高度に純粋なペメトレキセド二酸およびその調製方法
US8088919B2 (en) * 2006-08-14 2012-01-03 Sicor Inc. Crystalline forms of pemetrexed diacid and processes for the preparation thereof
KR101083230B1 (ko) 2006-08-14 2011-11-11 시코르, 인크. 페메트렉세드 이산의 동결 건조된 약학적 허용염의 제조 방법
EP2086323A4 (en) * 2006-11-03 2010-01-06 Univ Maryland METHOD OF USE OF SAHA AND BORTEZOMIB FOR THE TREATMENT OF MULTIPLE MYELOMA
EP2129674A2 (en) * 2007-04-03 2009-12-09 Dr. Reddy's Laboratories Ltd. Solid forms of pemetrexed
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
EP2072518A1 (en) * 2007-12-23 2009-06-24 Sun Pharma Advanced Research Company Limited Stable Amorphous Form of Pemextred Disodium
EP2334685A4 (en) * 2008-09-08 2011-10-26 Reddys Lab Ltd Dr AMORPHOUS PEMETREXED DISODIUM
WO2010030598A2 (en) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Pharmaceutical formulations comprising pemetrexed
CN101684121B (zh) 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
CN102050825B (zh) * 2009-11-05 2014-12-17 上海创诺制药有限公司 制备培美曲塞二钠2.5水结晶的方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
CN102372719B (zh) * 2010-08-26 2013-10-30 齐鲁制药有限公司 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
US9051322B2 (en) 2011-03-23 2015-06-09 Scinopharm Taiwan, Ltd. Process for the production of a pemetrexed salt
JP5826371B2 (ja) * 2011-03-25 2015-12-02 サイノファーム タイワン リミテッド ペメトレキセド塩の製造方法
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
CN102911176B (zh) * 2012-10-10 2015-07-22 德州德药制药有限公司 一种培美曲塞二钠的制备方法
WO2014060959A1 (en) * 2012-10-17 2014-04-24 Shilpa Medicare Limited Crystalline pemetrexed dipotassium process
EP2953616A2 (en) 2013-02-06 2015-12-16 Cipla House Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
EP3308770A1 (en) 2013-04-12 2018-04-18 Actavis Group PTC EHF Pemetrexed formulation
KR101485243B1 (ko) 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
JP6248189B2 (ja) 2013-06-14 2017-12-13 シントン・ベスローテン・フェンノートシャップ 安定な抗がん剤のアルギニン塩とそれを含む組成物
WO2015008221A1 (en) 2013-07-16 2015-01-22 Dr. Reddy’S Laboratories Limited Novel crystalline forms of pemetrexed tromethamine salts
PL3040074T3 (pl) 2013-10-03 2019-03-29 Fujifilm Corporation Preparat iniekcyjny i sposób jego wytwarzania
NZ630292A (en) * 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
NZ630299A (en) 2014-06-30 2014-11-28 Shilpa Medicare Ltd Pemetrexed dipotassium formulations
CA2962383C (en) 2014-10-30 2019-10-08 Scinopharm Taiwan, Ltd. Crystalline forms of pemetrexed diacid and manufacturing processes therefor
CN105566328B (zh) * 2014-11-06 2018-04-24 博瑞生物医药（苏州）股份有限公司 培美曲塞二酸多晶型的制备方法
CN109906071A (zh) * 2017-10-10 2019-06-18 太阳制药工业公司 培美曲塞的静脉输注剂型

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US5416211A (en) * 1992-09-25 1995-05-16 Eli Lilly And Company Process for preparing 5-substituted pyrrolo-[2,3-d]pyrimidines
AU4163197A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Nonclassical pyrrolo{2,3-d}pyrimidine antifolates
ZA987550B (en) * 1997-09-26 2000-02-21 Lilly Co Eli Processes and intermediates useful to make antifolates.
IL135190A (en) * 1997-09-26 2005-03-20 Lilly Co Eli Processes and intermediates useful to make antifolates
WO2001014379A2 (en) * 1999-08-23 2001-03-01 Eli Lilly And Company A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor

Also Published As

Publication number Publication date
DK1259513T3 (da) 2004-01-12
CN1406238A (zh) 2003-03-26
UA72791C2 (uk) 2005-04-15
PL208061B1 (pl) 2011-03-31
EG24073A (en) 2008-05-11
AU777047B2 (en) 2004-09-30
DE60100750D1 (de) 2003-10-16
CZ303772B6 (cs) 2013-05-02
KR20020075449A (ko) 2002-10-04
CA2400155A1 (en) 2001-08-30
MXPA02008242A (es) 2002-11-29
CZ20022875A3 (cs) 2003-02-12
PL356423A1 (en) 2004-06-28
DE60100750T2 (de) 2004-07-29
NO20023974D0 (no) 2002-08-21
CN1183135C (zh) 2005-01-05
IL150480A (en) 2007-12-03
IL150480A0 (en) 2002-12-01
HUP0204232A3 (en) 2006-01-30
TWI237024B (en) 2005-08-01
SV2002000321A (es) 2002-07-16
HRP20020701A2 (en) 2003-12-31
PE20011082A1 (es) 2001-10-22
WO2001062760A3 (en) 2001-12-06
NZ519796A (en) 2003-01-31
NO20023974L (no) 2002-08-21
ZA200205265B (en) 2003-11-11
SI1259513T1 (en) 2003-12-31
CA2400155C (en) 2009-09-15
US20030216416A1 (en) 2003-11-20
SK287375B6 (sk) 2010-08-09
KR100744917B1 (ko) 2007-08-01
WO2001062760A2 (en) 2001-08-30
EP1259513A2 (en) 2002-11-27
EP1259513B1 (en) 2003-09-10
NO323422B1 (no) 2007-04-30
AU3445101A (en) 2001-09-03
US7138521B2 (en) 2006-11-21
JP4846158B2 (ja) 2011-12-28
JP2003530321A (ja) 2003-10-14
DZ3283A1 (fr) 2001-08-30
MY124784A (en) 2006-07-31
AR029471A1 (es) 2003-07-02
EA004684B1 (ru) 2004-06-24
ATE249462T1 (de) 2003-09-15
ES2206403T3 (es) 2004-05-16
EA200200905A1 (ru) 2003-02-27
HK1051856A1 (en) 2003-08-22
PT1259513E (pt) 2004-02-27
BR0108604A (pt) 2002-11-19
HUP0204232A2 (hu) 2003-04-28
HRP20020701B1 (en) 2011-02-28
HU229704B1 (en) 2014-05-28
SK11862002A3 (sk) 2003-01-09

Similar Documents

Publication Publication Date Title
CO5261585A1 (es) Nueva forma cristalina del acido n-[4-[2-(2-amino-4,7- dihidro-4-oxo-3h-pirrolo[2,3-d]pirimidin-5-il)etil] benzoil]-l-glutamico y procedimiento para su preparacion
CO5271736A1 (es) Forma triturada
AR077416A2 (es) Compuesto polimorfo estable de flibanserina , procedimiento industrial para su preparacion y uso del mismo para preparar medicamentos
FI964815A0 (fi) Piperatsiinijohdoksia 5-HT1A antagonisteina
CA2093577A1 (en) Alkyl or alkoxy substituted s-heterocyclic retinoids
EA200300107A1 (ru) Кристаллические формы трет-бутиламиновой соли периндоприла
CO5170486A1 (es) Compuestos de imidazoles sustituidos que tienen actividad an tibacteriana
NI200500031A (es) Nuevos procesos para la sintesis de ivabradine y ademas sales que la contienen con un acido aceptable farmaceuticamente.
BR0210434A (pt) Método para produzir produto a partir de rejeito de fibra de vidro
EA200300834A1 (ru) Антагонисты фактора, высвобождающего кортикотропин
EA200100194A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ ETO2C-CH2-(R)Cgl-Aze-Pab-OH
EP1493213A4 (en) IMPROVED INTRACAVITY PRODUCTION BY FOURTH HARMONIC RESONANCE USING NON-COATED BREWSTER SURFACES
BRPI0412391A (pt) formulação farmacêutica compreendendo levotiroxina sódica
JP2002544191A5 (es)
SV2002000132A (es) Una nueva forma cristalina de clorhidrato de 6-hidroxi-3-(4-[2-(piperidin-1-il)etoxi]fenoxi) -2-(4-metoxifenil)benzo[b]tiofeno ref. x-11357.
AR027624A1 (es) Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos
CO5170530A1 (es) Procedimietno para preparar derivados de 10,11-metanobenzosuberano
PL369896A1 (en) A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
CO5180571A1 (es) Forma cristalina iii de la n-(4-dimetilaminonaftalen-1 sulfonilamino ) fenil)-3-hidroxi-2,2-dimetilpropionamida
Bouaicha et al. La vasectomia nell’ariete.
ES502777A0 (es) Procedimiento para la preparacion de derivados de imidazol
CO5310528A1 (es) Nucleo absorbente, un proceso de fabricacion del nucleo absorbente y un articulo absorbente descartable con el nucleo absorbente
PE20011255A1 (es) FORMULACIONES ESTABILIZADAS DE 6-HIDROXI-3-(4-[2-(PIPERIDIN-1-IL)ETOXI]FENOXI)-2-(4-METOXIFENIL)BENZO[b]TIOFENO Y SUS SALES
BR0112876A (pt) Processo para preparação de discodermolida e seus análogos
BR0114281A (pt) Processo para o isolamento de etidronato dissódico utilizável farmaceuticamente

Legal Events

Date Code Title Description
FC Application refused